Today the British Medical Journal shared their perspective on GALENOS. The article explains why this new systematic review of available literature was needed, and how it might accelerate research into anxiety, depression and psychosis.
The GALENOS online resource will make it easier for everyone, including patients, funders and researchers to access and review the scientific literature that is currently available about anxiety, depression and psychosis.
In anxiety, depression and psychosis, there has been frustratingly slow progress in developing new therapies that make a substantial difference in practice, as well as in predicting which treatment will work for whom, and in what contexts. We need to better understand the causes of mental health conditions, develop safe and effective early interventions, and improve our capabilities to provide timely diagnosis. Facilitating in-depth access to existing evidence is one way to help achieve these goals.
The main output from GALENOS will be a series of free-to-access systematic reviews that will be regularly updated with the best available scientific literature. These reviews will analyse research from animal studies through to clinical studies in humans and will provide reliable evidence which will help identify promising areas of research, early on in the process of mental health disorders, as well as identifying gaps in knowledge to be covered by future studies.
By making the best use of existing data, our hope is that GALENOS will accelerate progress in developing a better understanding and new treatments for the prevention and early intervention of anxiety, depression, and psychosis.
GALENOS is an international collaboration of mental health clinicians, researchers and experiential advisors, and is supported by Wellcome.
You can read the BMJ article here: https://mentalhealth.bmj.com/content/26/1/e300759?rss=1
